Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period

DUBLIN, September 30, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that shareholders of Movetis NV have
tendered 99.18% of the shares of Movetis (Euronext Brussels: MOVE) during the
initial acceptance period of the tender offer which closed on September 27,
2010. The shares tendered into the tender offer are expected to be settled on
October 12, 2010.

In addition, warrant holders of Movetis have agreed to tender 727,911 new
shares to be issued on the settlement date following the conditional exercise
of warrants.

Accordingly, Shire Holdings Luxembourg S.à r.l. (a subsidiary of Shire
plc) will own 99.21% of the outstanding shares of Movetis on the settlement
date of the tender offer.

Squeeze-Out Procedure

Shire has decided to proceed with a squeeze-out of those shares not
tendered to the offer in accordance with applicable Belgian legislation. In
this regard, an additional tender offer period will open, on the same terms,
on October 12, 2010 and close on November 2, 2010 at 4 pm CET.

Shares tendered into the additional tender offer are expected to be
settled on November 8, 2010. Shares and warrants not tendered to the
additional tender offer shall be deemed transferred to Shire Holdings
Luxembourg S.à r.l. by operation of law on November 8, 2010. Payment of the
offer price for shares and warrants not tendered to the additional tender
offer will be deposited with the Deposito-en Consignatiekas/Caisse des Dépôts
et Consignations in Belgium.

At the close of the reopened tender offer, the shares in Movetis will be
delisted from Euronext Brussels. The last trading day will therefore be
November 2, 2010.

Shire's offer is EUR19 in cash for each outstanding Movetis share.

The prospectus relating to the tender offer and the squeeze-out is
available at no cost at the counters of the Receiving and Paying Agents in
Belgium The Royal Bank of Scotland N.V. or by phone (+3120/4643707), KBC
Securities NV, KBC Bank NV, CBC Banque SA or by phone 03/283 29 70 (KBC
telecenter) or 0800/92 020 (CBC Banque). An electronic version of the
prospectus is available on the following websites:
www.kbcsecurities.be, www.kbc.be, www.cbcbanque.be and
www.shire.com.

Important Notice

With the exception of the CBFA, no governmental or other authority in any
other jurisdiction has approved the prospectus, the tender offer or the
squeeze-out. The tender offer is made only in Belgium. Neither this
announcement nor the prospectus constitutes an offer to buy or to sell, or a
solicitation to any person in any jurisdiction to buy or sell, any security
where such an offering or solicitation is not permitted or is unlawful. No
action has or will be taken outside Belgium to enable a public offer in any
jurisdiction where action would be required for that purpose. Neither the
prospectus, nor the acceptance forms or exercise form, or other information
relevant to the tender offer in Belgium may be supplied to the public in any
jurisdiction outside Belgium where a registration or other obligation may be
required with regard to a public offer to buy or sell securities. Any failure
to comply with these restrictions may constitute a violation of applicable
financial laws and regulations in other jurisdictions. Shire explicitly
declines any liability for breach of these restrictions by any person.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire's in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's
website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, the Company's results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks associated with: the inherent uncertainty of research,
development, approval, reimbursement, manufacturing and commercialization of
the Company's Specialty Pharmaceutical and Human Genetic Therapies products,
as well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the Company's
products; the Company's ability to manufacture its products in sufficient
quantities to meet demand; the impact of competitive therapies on the
Company's products; the Company's ability to register, maintain and enforce
patents and other intellectual property rights relating to its products; the
Company's ability to obtain and maintain government and other third-party
reimbursement for its products; and other risks and uncertainties detailed
from time to time in the Company's filings with the Securities and Exchange
Commission.

    For further information please contact:

    Investor Relations

    Eric Rojas (erojas@shire.com)
    +1-781-482-0999

    Media

    Jessica Mann (jmann@shire.com)
    +44-1256-894-280

    Matthew Cabrey (mcabrey@shire.com)
    +1-484-595 8248

Investor Relations: Eric Rojas (erojas at shire.com), +1-781-482-0999. Media: Jessica Mann (jmann at shire.com), +44-1256-894-280, Matthew Cabrey (mcabrey at shire.com), +1-484-595 8248